We recognize the incredible burden that cancer has on patients and those who care for them. Our relentless pursuit to advance scientific discovery is matched only by our determination to bring solutions to patients.
We are building on a rich legacy in oncology with a rejuvenated pipeline and a renewed commitment to bring novel treatment options to patients with unmet medical needs. Today, Sanofi Genzyme has a portfolio of medicines indicated across a variety of cancers, including skin, prostate, lung, colon, breast and blood.
Where science meets determination
The World Health Organization (WHO) estimates that cancer is the second leading cause of death globally, and that there are more than 100 different kinds of cancer involving numerous pathways and genetic mutations. Our ambition is to contribute meaningful solutions for patients who are battling cancer through drug discovery and development that is rooted in strong science and innovative technologies.
Our oncology pipeline of investigational medicines is flourishing and includes a dozen compounds in all phases of clinical trials. Our strategy is to focus on four areas of cancer – skin, blood, breast and lung – by building a portfolio of complementary molecules. Our research is focused in two approaches: immuno-oncology and molecular oncology.
In immuno-oncology, our research approach is focused on addressing the underlying mechanisms of resistance to immunotherapies. We aim to make tumors receptive to checkpoint inhibitor treatments, which are capable of enabling the immune system to attack tumor cells.
Our molecular oncology research approaches include targeted therapeutics that aim to exploit genetic changes found in tumors but not normal cells - drugs that suppress hormone-driven cancers, as well as antibody-drug conjugates (ADCs) that utilize monoclonal antibodies to deliver cytotoxic anticancer drugs into tumor cells minimizing systemic exposure and effects on normal tissues.
We are testing a wide diversity of drug combinations through a variety of technology platforms to invent differentiated molecules that tackle targets in immuno-oncology and molecular oncology. Because cancer tumors often mutate, simultaneous treatment with multiple therapeutics is a promising approach in addressing difficult-to-eradicate cancers.
Determined for patients around the world
Above from left to right: Bernard, multiple myeloma, France; Danielle, multiple myeloma, USA; John, prostate cancer, USA